DocSym
β
Searchsearch
Search
(Y52.3) Coronary vasodilators, not elsewhere classified
More details coming soon
72 652 in individuals diagnosis coronary vasodilators, not elsewhere classified confirmed
1 277 deaths with diagnosis coronary vasodilators, not elsewhere classified
2% mortality rate associated with the disease coronary vasodilators, not elsewhere classified
Diagnosis coronary vasodilators, not elsewhere classified is diagnosed Women are 16.51% more likely than Men
30 329
Men receive the diagnosis coronary vasodilators, not elsewhere classified
634 (2.1 %)Died from this diagnosis.
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
42 323
Women receive the diagnosis coronary vasodilators, not elsewhere classified
643 (1.5 %)Died from this diagnosis.
Risk Group for the Disease coronary vasodilators, not elsewhere classified - Men aged 60-64 and Women aged 75-79
In Men diagnosis is most often set at age 0-5, 10-14, 30-34, 50-64, 70-89
Less common in men the disease occurs at Age 0-1, 5-9, 15-29, 35-49, 65-69, 90-95+Less common in women the disease occurs at Age 0-19, 25-29, 55-59, 95+
In Women diagnosis is most often set at age 20-24, 30-54, 60-94
Disease Features coronary vasodilators, not elsewhere classified
Absence or low individual and public risk
Coronary vasodilators, not elsewhere classified - what does this mean
Coronary vasodilators, not elsewhere classified are a group of drugs that act on the coronary arteries to relax them and increase blood flow to the heart, thus improving oxygen supply to the heart muscle. they act by blocking the action of certain hormones or by blocking calcium channels, leading to relaxation of the smooth muscle cells in the walls of the coronary arteries.
What happens during the disease - coronary vasodilators, not elsewhere classified
Coronary vasodilators are medications that work to relax and widen the coronary arteries, allowing for increased blood flow. this increased blood flow helps to reduce the workload of the heart, and helps to reduce the risk of developing coronary artery disease. the mechanism of action of these medications is to activate the enzyme guanylate cyclase, which in turn increases the levels of cyclic guanosine monophosphate (cgmp). this increase in cgmp helps to cause the relaxation of the smooth muscle cells in the walls of the coronary arteries, resulting in vasodilation and improved blood flow.
Clinical Pattern
More details coming soon
How does a doctor diagnose
- Physical Exam
- Blood Tests
- Echocardiogram
- Electrocardiogram (ECG)
- Stress Test
- Cardiac Catheterization
- Coronary Angiography
- Chest X-Ray
- CT Scan
- MRI
- Ultrasound
Treatment and Medical Assistance
Main goal of the treatment: To reduce the symptoms of Coronary Vasodilators, not elsewhere classified.
- Prescription of medications to reduce symptoms, such as ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers
- Lifestyle changes such as increased physical activity and healthy diet
- Smoking cessation and avoidance of other risk factors, such as high cholesterol and high blood pressure
- Surgery to open blocked arteries, such as angioplasty or coronary artery bypass grafting
- Monitoring of heart rhythm with an electrocardiogram (ECG) or Holter monitor
- Cardiac rehabilitation to improve cardiovascular health
11 Days of Hospitalization Required
Average Time for Outpatient Care Not Established
Coronary vasodilators, not elsewhere classified - Prevention
The best way to prevent coronary vasodilators, not elsewhere classified is to maintain a healthy lifestyle with regular exercise, a balanced diet, and stress management. additionally, it is important to monitor blood pressure and cholesterol levels, and to seek medical advice if symptoms arise.